The eukaryotic cell cycle is regulated by sequential activation and inactivation of cyclin-cyclin-dependent kinase (Cdk) complexes. In this work, we screened human cDNAs that can rescue yeast Saccharomyces cerevisiae from lethality caused by ectopic expression of human cyclin E and isolated a cDNA encoding ESXR1, a pairedlike homeodomain-containing protein with a unique C-terminal proline-rich repeat region. In adult tissues, ESXR1 is primarily expressed in the testis. We demonstrate that ESXR1 prevents degradation of ubiquitinated cyclins in human cells. Accordingly, elevation of ESXR1 level results in accumulation of cyclin A and cyclin B1 and thereby provokes M-phase arrest. In human cells, the 65-kDa full-length ESXR1 protein is capable of proteolytically processing into N-terminal 45-kDa and C-terminal 20-kDa fragments. The C-terminal fragment, containing a proline-rich repeat region, is localized to the cytoplasm and displays the ability to inhibit cyclin degradation. In contrast, the N-terminal fragment, containing a pairedlike homeodomain, is localized exclusively in the nucleus, suggesting that it plays a role in transcription. Our results indicate that proteolytic processing of ESXR1 plays a role in concerted regulation of the cell cycle and transcription in human cells.
Introduction
Transition through phases of the cell cycle is regulated by the temporal activation and inactivation of heterodimeric kinases composed of cyclin and cyclin-dependent kinase (Cdk) species. Different combinations of cyclins and Cdks phosphorylate and thereby functionally modify a distinct set of cellular target molecules specifically required for the transition and/or progression of each cell cycle phase (D'Urso et al., 1990; Solomon et al., 1990; Morgan, 1995; Nurse, 2000) . Progression of the cell cycle from G1 to S phase requires the activation of cyclin D-Cdk4/6 and cyclin E-Cdk2, resulting in phosphorylation of substrates, including the retinoblastoma family of tumor suppressor proteins (Weinberg, 1995) . Cyclin E and cyclin A play important roles in the initiation of DNA replication and subsequent progression through to S phase. Both cyclins bind to Cdk2 and their levels are strictly regulated by transcriptional and proteolytic mechanisms (Sherr, 1994; King et al., 1996; DeSalle and Pagano, 2001) . Cyclin E level rapidly increases in mid-to-late G1 phase (Dulic et al., 1992) , and cyclin E-Cdk2 activity peaks at G1/S transition. Cyclin A level starts to increase at the beginning of S phase and is stable until cells enter mitosis, where they are rapidly degraded by ubiquitindependent proteolysis (Su, 2001) .
The onset of M phase is controlled by a cascade composed of protein kinases such as Wee1 and Mik1 and phosphatases such as Cdc25, which collectively regulate Cdk kinase activity (Featherstone and Russell, 1991; Lundgren et al., 1991; Millar et al., 1991) . In mammalian cells, the level of cyclin B-Cdc2 kinase activity rises dramatically at the G2/M boundary. Although cyclin B-Cdc2 activation is essentially required for the progression of prophase and metaphase of mitosis, degradation of cyclin B by anaphasepromoting complex/cyclosome (APC/C) triggers entry to anaphase and subsequent exit from mitosis (Guadagno and Newport, 1996; Chang et al., 2003) . Recent studies have further shown that active cyclin A-Cdk2 complex is also essential for M-phase entry and progression to mid-prophase (Furuno et al., 1999) . Subsequent degradation of cyclin A in prometaphase by 26S proteasome pathway is required for chromosome alignment and anaphase progression (den Elzen and Pines, 2001 ).
The activities of cyclin-Cdk complexes during the cell cycle are regulated at multiple levels, including transcription of cyclin genes, regulatory phosphorylation of cyclins and Cdks, association with Cdk inhibitors as well as proteolytic degradation of cyclins. To further investigate mechanisms underlying the regulation of cyclin-Cdk activity during the cell cycle, we screened additional human molecules that functionally interact with human cyclins in yeast Saccharomyces cerevisiae and isolated a cDNA clone that encodes a novel paired-like homeodomain-containing protein, ESXR1 (Fohn and Behringer, 2001) . ESXR1 is specifically expressed in the testis and is thought to function as a sequence-specific transcription factor. In the present study, we found that ESXR1 has the ability to inhibit degradation of polyubiquitinated cyclin A and cyclin B1 and thereby arrest the cell cycle at early M phase. We also found that ESXR1 is proteolytically processed into two peptide fragments in human cells, an N-terminal homeodomain-containing fragment and a C-terminal fragment that inhibits cyclin degradation. Our results indicate that ESXR1 may coordinately regulate the cell cycle and transcription during spermatogenesis.
Results

Cloning of ESXR1 cDNA by yeast genetic screening
Inducible expression of human cyclin E cDNA in S. cerevisiae by the galactose-dependent GAL promoter provokes cell death (Figure 1a, d ). The lethality of cyclin E in yeast was overcome by the coexpression of a p27
Kip1
Cdk inhibitor (Figure 1b, e) . Accordingly, we screened human cDNAs that can rescue yeast cells from the lethality of cyclin E. Upon introduction of a HeLa cellderived human cDNA expression library into yeast cells that inducibly express cyclin E, we obtained a yeast transformant that grew in the presence of cyclin E. The cDNA was then isolated from the yeast transformant and the sequence was determined. The same gene was recently cloned in silico as a human gene structurally related to the paired-like mouse homeobox gene Esx1/ Spx1 (Branford et al., 1997; Li et al., 1997) and has been designated ESXR1 (Fohn and Behringer, 2001 ). However, the biological roles of ESXR1 as well as its product ESXR1 are not known. As deduced from the cDNA sequence, the human ESXR1 protein consists of 406-amino-acid residues and possesses a paired-like homeodomain (Figure 1g) . Notably, there are 15 repeats of a nine-amino-acid, proline-rich motif (GPPMAP(V/L)PP) in the C-terminal region (Figure 1h) . A human genome database revealed that the ESXR1 gene consists of exons and introns and is located at Xq22.1-22.3.
The ESXR1 cDNA was capable of rescuing yeast cells from cyclin E cytotoxicity (Figure 1c , f). Since cyclin E was detectable in a galactose-dependent manner in the ESXR1-expressing yeast cells, the possibility that ESXR1 inhibited cyclin E expression in yeast was excluded (data not shown).
Expression and processing of ESXR1 in human cells
By Northern blot analysis of human adult tissues, ESXR1 mRNA was detectable in the testis but not in other tissues (Figure 2a) . In human cancer cell lines, ESXR1 mRNA was detectable in NCC-IT male germcell-derived tumor cells and HeLa cells, but not in AGS gastric carcinoma cells by RT-PCR (Figure 2b ).
To detect ESXR1 protein, we raised a rabbit polyclonal antiserum by immunizing a synthetic peptide corresponding to the N-terminal 17-amino-acid residues of ESXR1 and examined the expression of ESXR1 in NCC-IT cells by immunoblotting. As shown in Figure 1 Cloning of human ESXR1 by yeast genetic screening. (a-f) A diploid yeast strain that express human cyclin E cDNA was transfected with control vector, p27
Kip1 expression vector or ESXR1 expression vector. The cDNAs were inducibly expressed under the GAL promoter. Yeast transformants were streaked to 2% glucoseor 2% galactose-containing plates (a, d: control; b, e: p27 Kip ; c, f: ESXR1). Plates were incubated at 301C for 2 days and photographed. (g) Amino-acid sequence of the human ESXR1 protein. The underline represents the paired-like homeodomain, and the light and dark gray boxes represent the proline-rich repeat sequences. Open box indicates a putative nuclear-localization signal (NLS). (h) Schematic representation of ESXR1 and the unique C-terminal repeat region Cyclin regulation by ESXR1 homeoprotein H Ozawa et al Figure 2c , anti-ESXR1 detected a 45-kDa band, which disappeared in the presence of the ESXR1 peptide but not Cdk2 peptide. When HeLa cells were immunostained with anti-ESXR1, the nucleus was specifically stained and, again, the staining was abolished in the presence of ESXR1 peptide (Figure 2d ). We next examined ESXR1 protein expression in human cell lines by immunoblotting. A 45-kDa band was also detected in lysates prepared from HeLa cells or JKT-1 seminoma cells but not in lysates from U2-OS osteosarcoma cells or AGS cells (Figure 2e) . The relationship between the 45-kDa band and the ESXR1 protein was examined by knockdown of ESXR1 expression in HeLa cells with the use of ESXR1-specific siRNA. As demonstrated in Figure 2f , the 45-kDa band was reduced in cells treated with ESXR1 siRNA. Collectively, these results indicate that the 45-kDa band detected by anti-ESXR1 is ESXR1.
Next, we examined ESXR1 expression in human normal tissues. As expected, the 45-kDa band was detectable in lysates prepared from the testis (Figure 2g ). In this anti-ESXR1 immunoblotting, we noticed that, in addition to the major 45-kDa band, a minor 65-kDa band was also detectable in lysates from the testis. A faint 65-kDa band was also present in lysates from NCC-IT or JKT-1 cells (Figure 2e) .
To determine the relationship between 45-and 65-kDa bands, we transiently expressed a full-length ESXR1 cDNA in U2-OS cells, and lysates prepared were subjected to anti-ESXR1 immunoblotting. The cDNA-derived ESXR1 was detected as 65-and 45-kDa bands (Figure 3a) . Since anti-ESXR1 specifically recognizes N-terminal ESXR1, this finding raised the possibility that the 65-kDa band was the full-length protein and that the 45-kDa band was a C-terminal truncated fragment. Accordingly, we made an Nterminal Myc-and C-terminal Flag-tagged ESXR1 (Myc-ESXR1-Flag) and transiently expressed the double-tagged ESXR1 in U2-OS cells. As shown in Figure 3b , both 65-and 45-kDa bands were detected by anti-Myc immunoblotting, whereas 65-and 20-kDa (arrowhead) bands were detected by anti-Flag immunoblotting. These results indicate that the full-length ESXR1 is a 65-kDa protein, which is proteolytically cleaved to the N-terminal 45-kDa fragment, ESXR1-N, and the C-terminal 20-kDa fragment, ESXR1-C. To pursue this further, we established a U2-OS-derived, stable transfectant clone, U2/tetESXR1, that inducibly expresses the N-terminal Myc-tagged ESXR1 in the presence of doxycycline (Dox). The level of ESXR1 inducibly expressed was, however, an order of magnitude lower than that expressed in U2-OS cells by transient transfection (data not shown). Kinetics of (Figure 3c ). Upon induction, the 65-kDa ESXR1 species was detectable at 6 h. A faint 45-kDa band was also detectable at that time point. Intriguingly, levels of the 45-kDa band increased with passage of time, whereas those of the 65-kDa band did not. The observation indicates that the 45-kDa species is generated by proteolytic processing of the 65-kDa ESXR1 protein.
The predominant expression of the 45-kDa species in certain tumor cell lines suggests that ESXR1 is efficiently processed to 45-and 20-kDa fragments in those cells. We further investigated whether the ESXR1 protein processing is dependent on cell cycle. To this end, we arrested U2/tetESXR1 cells either in S phase by treating them with hydroxyurea (HU) or in G2/M phase by treating them with nocodazole. As demonstrated in Figure 3d , the treatment did not have any effect on the ESXR1 processing.
ESXR1 accumulates cyclins in human cells
Since ESXR1 counteracted cyclin E toxicity in yeast cells, we carried out an experiment to determine whether ESXR1 has a Cdk inhibitor activity. To this end, we expressed a glutathione-S-transferase (GST)-full-length ESXR1 fusion protein in Escherichia coli (E. coli) and purified it. A major species of the purified GST-ESXR1 protein was detected as a 65-kDa band, indicating that the C-terminal region of ESXR1 was again cleaved in bacteria as was the case in mammalian cells ( Figure 4a , upper panel). The purified GST-ESXR1 or GST-p21 Cip1 fusion protein was added to the in vitro kinase reaction of cyclin E-Cdk2 complexes. In contrast to 0.1 mg of GST-p21
Cip1
, which potently inhibited cyclin E-Cdk2 kinase activity ( Figure 4a , lane 4), 1.0 mg of GST-ESXR1 did not have any effect on cyclin E-Cdk2 (lane 7). Also, the GST-ESXR1 fusion protein was not phosphorylated by cyclin E-Cdk2 in vitro (Figure 4b ). The result argues against the idea that ESXR1 functions as a Cdk inhibitor, although the possibility remains that the C-terminal region of ESXR1, which might have been chopped off in E. coli, binds and inhibits cyclin-Cdk. However, we think that it is less likely because the 65-kDa ESXR1 protein did not physically interact with a cyclin E-Cdk2 complex in U2/tetESXR1 cells ( Figure 4c ).
In the absence of data that support ESXR1 to be a Cdk inhibitor, we next investigated the effect of ESXR1 U2/tetESXR1 cells were incubated with or without doxycycline (Dox) and were harvested at indicated times. ESXR1 levels were quantitated using a luminescent image analyser. (d) U2/tetESXR1 cells were incubated with Dox for 24 h (lane 1). U2/tetESXR1 cells were cultured in the presence of 5 mM HU for 24 h, and were incubated with Dox in the presence of HU for another 24 h (lane 2). U2/tetESXR1 cells were cultured in the presence of 50 ng/ml nocodazole for 12 h. The cells were incubated with Dox in the presence of nocodazole for another 24 h (lane 3). Cells were subjected to cell cycle analysis or immunoblotting analysis. Numbers below each panel represent intensities of 45-kDa ESXR1, and normalized to a value of 100 for respective 65-kDa ESXR1 on the levels of cyclins, we ectopically coexpressed ESXR1 together with cyclin A, B1, E or pRB-related p130 in asynchronously growing U2-OS cells. Whereas ESXR1 did not have any effect on the level of p130, the level of cyclin A, B1, E was greatly increased when ESXR1 was coexpressed (Figure 5a ). An increase in the level of cyclin A or B1 was also observed when ESXR1 was inducibly expressed in asynchronously growing U2/ tetESXR1 cells (Figure 5b ). Since ESXR1 did not have any effect on the activity of the cyclin E promoter, the possibility that ESXR1 transactivated endogenous cyclin genes was excluded ( Figure 5c ). 
Inhibition of degradation of ubiquitinated cyclins by ESXR1
The above-described observations suggested that ESXR1 induced accumulation of cyclins by inhibiting their degradation. To investigate this possibility, we performed a pulse-chase experiment using the U2/ tetESXR1 cells, in which induction of ESXR1 elicited accumulation of cyclin A and cyclin B1 ( Figure 5b ). As shown in Figure 5d , the biological half-life of cyclin A was significantly prolonged in the presence of ESXR1. Since cyclins are known to be degraded by an ubiquitin-dependent 26S proteasome pathway (Glotzer et al., 1991) , we transiently coexpressed Flag-tagged ubiquitin and cyclin A in U2-OS cells and examined cyclin ubiquitinization in the presence or absence of ESXR1 or a proteasome inhibitor, MG132 (Figure 5e ). When 26S proteasome was inhibited by MG132, polyubiquitinated cyclin A bands became detectable as a ladder. A polyubiquitinated ladder of cyclin A was also detected in cells expressing ESXR1. Consistently, possible polyubiquitinated forms of cyclins were also detected in the anti-HA immunoblottings in Figure 5a . From this observation, we concluded that ESXR1 prevents ubiquitinated cyclins from degradation.
Effect of ESXR1 on the cell cycle
The above observations indicated that ESXR1 plays a role in cell cycle regulation. Accordingly, we next examined the effect of ESXR1 on the cell cycle. As shown in Figure 6a , transient expression of ESXR1 in U2-OS cells caused a dramatic increase in cells of G2/ M phase. Consistently, induction of ESXR1 in asynchronously proliferating U2/tetESXR1 cells resulted in strong cell growth inhibition (Figure 6b ), which was associated with cell cycle arrested at the G2/M phase ( Figure 6c) . To investigate the cell cycle-arrest point by ESXR1 in more detail, the U2/tetESXR1 cells were cultured in the presence or absence of Dox for 48 h. Prior to harvest, cells were treated with colcemid, an inhibitor of microtubule assembly, for another 1 h. In the absence of ESXR1, cells were specifically arrested at metaphase by colcemid, and chromosomal condensation in these cells was mature (Figure 6d, arrowhead) . On the other hand, the ESXR1-expressing cells did not show nuclear membrane breakdown and chromosomal condensation was mostly premature in those cells (Figure 6d, right panel) . The result indicates that expression of ESXR1 in cycling cells prevents prophase-metaphase transition and halts the cell cycle at early M phase of the cell cycle.
To exclude a possibility that elevated levels of cyclins in cells expressing ESXR1 are simply due to cell cycle arrest at early M phase, when cyclin A and cyclin B1 are at their highest levels, we arrested U2/tetESXR1 cells in S phase by treating them with HU ( Figure 7a ). It is known that synthesis of cyclin B continues after the end of mitosis. However, because APC/C is active from the end of mitosis until the onset of S phase, B-type cyclins do not accumulate during G1 and early S phases (Brandeis and Hunt, 1996) . In the case of cyclin A, whereas it is transcriptionally activated in late G1, its accumulation is inhibited by APC/C until entering into S phase. With this notion in mind, the HU-treated cells were induced to express ESXR1. As shown in Figure 7a , the levels of cyclin A and cyclin B1 were significantly higher in ESXR1-expressing cells than in cells without ESXR1, most probably due to inhibition of their degradation by ESXR1 during G1 and early S phases. In contrast, the level of p130 or b-catenin was not affected by ESXR1. Thus, the ability of ESXR1 to stabilize protein exhibits a certain specificity among various ubiquitinated proteins. Consistent with the above observation, specific accumulation of polyubiquitinated cyclin A was observed in S-phase-arrested cells only when ESXR1 was present (Figure 7b ). Consistent with this notion, cell cycle progression of nocodazolearrested cells from metaphase to anaphase was inhibited by ESXR1 (data not shown). Since cyclin B1 is not only unstable during mitotic exit but also for an extended onset of S phase in mammalian cells (Brandeis and Hunt, 1996) , cyclin B1 level may be increased when ESXR1 is coexpressed in the presence of HU (Figure 7a ). We also arrested U2/tetESXR1 cells at metaphase, where cyclin B1 is degraded, by nocodazole and then induced ESXR1 by Dox in the metaphase-arrested cells. Again, the level of cyclin B1 was significantly higher in cells expressing ESXR1 than in cells lacking ESXR1 (Figure 7c ). These data reinforce the conclusion that ESXR1 stabilizes cyclins regardless of the cell cycle phase.
Downregulation of ESXR1 decreases cyclin levels in human cells
To examine the biological relevance of the ESXR1 activity on cyclin turnover, we next investigated the effect of loss of function of ESXR1 on cells. To this end, we transfected ESXR1-specific siRNA into U2/ tetESXR1 cells. As shown in Figure 8a and b, the siRNA-treatment greatly reduced ESXR1 levels and neutralized the cell cycle inhibitory activity of ESXR1. Next, treatment of asynchronously proliferating HeLa cells with the siRNA resulted in reduction of the level of endogenous ESXR1, which was associated with a decrease in the level of cyclin B1 (Figure 8c) . The results provide direct evidence that endogenously expressed ESXR1 is involved in the elevation of cyclin levels in HeLa cells. The siRNA treatment, however, did not alter the cell cycle profile of HeLa cells (data not shown). Hence, inhibition of cyclin expression by ESXR1 knockdown may be insufficient to alter cell cycle in HeLa cells. The observation therefore raises the possibility that the primary role of ESXR1 is to inhibit cell cycle upon it induction in particular cell types.
ESXR1 C-terminal repeat region is responsible for cyclin stability
Next, to determine the role of this ESXR1 processing in its biological activities, we generated three ESXR1 mutants, DN, DHD and DC (Figure 9a ). The DC and DN mutants correspond in size to the 45-and 20-kDa fragments of ESXR1, respectively. Each of the ESXR1 mutants was N-terminal Myc-tagged and transiently expressed in monkey COS-7 cells together with cyclin A (Figure 9b ). As expected from the result of ESXR1-N, the DC migrated much more slowly (45-kDa) ( Figure  9b , c) than that expected from the amino-acid sequence (25-kDa). Since the N-terminal region is very rich in charged amino acids, such strong bias in amino-acid constitution may result in unusual migration retardation of the N-terminal fragment. In contrast to the case with U2-OS cells, ESXR1 was hardly processed when expressed in COS-7 cells, indicating that activity of protease that cleaves ESXR1 is weak in the monkey cells (Figure 9b, d) . However, transient expression of ESXR1 in COS-7 cells elicited strong M-phase arrest (Figure 9d ). The result indicated that the full-length 65-kDa ESXR1 is also capable of inhibiting cell cycle. Accumulation of cyclin A was observed when the COS-7 cells were cotransfected with the wild-type ESXR1 and DN but not with DC (Figure 9b, upper panel) . Thus, the C-terminal proline-rich repeat region was required for the activity of ESXR1 to inhibit cyclin turnover. Furthermore, both the DHD and DN mutants were active in inhibiting the cell cycle at G2/M phase but that the DC mutant was incapable of arresting the cell cycle (Figure 9e) . From these observations, we concluded that the cell cycleregulatory activity of ESXR1 resides in the C-terminal proline-rich repeat region and that both the 65-kDa fulllength ESXR1 and the proteolytically processed 20-kDa fragment of ESXR1 act as a novel cell cycle regulator.
Differential localization of ESXR1 fragments in the cell
To determine the relationship between the biological activity and intracellular localization of ESXR1, we transiently expressed, wild-type or mutant ESXR1 protein in U2-OS cells. The results revealed that DHD and DN mutants were localized in the cytoplasm, whereas the DC mutant was exclusively localized in the nucleus (Figure 10a ). The strict nuclear localization of ESXR1-N can be explained by the existence of a NLS sequence present in the homeodomain. In cells transfected with Myc-tagged, wild-type ESXR1 cDNA, both the cytoplasm and nucleus were stained with anti-Myc, which specifically recognizes the N-terminal region of ESXR1. Since ESXR1-N exclusively localizes to the nucleus, this observation indicates that at least a certain fraction of the 65-kDa full-length protein is present in the cytoplasm. To pursue this point further, we transfected the Myc-ESXR1-Flag construct into U2-OS cells. In this experimental condition, Myc-ESXR1-Flag proteins are present as full-length 65-KDa, the ESXR1-N fragment and the ESXR1-C fragment in the cells (see Figure 3b) . As demonstrated in Figure 10b , both the cytoplasm and the nucleus were stained with anti-Myc, which recognizes the N-terminal ESXR1 region. On the other hand, anti-Flag antibody, which reacts with the C-terminal ESXR1 region, stained specifically the cytoplasm. The observation indicates that the full-length ESXR1 and the C-terminal ESXR1 fragment are localized in the cytoplasm.
Immunostaining of endogenous cyclin A in U2-OS cells expressing wild-type or mutant ESXR1 confirmed that the C-terminal region of ESXR1 is responsible for the accumulation of cyclin A (Figure 10c) . Consistent with the conclusion that ESXR1 inhibits degradation of ubiquitinated cyclins in the cytoplasm, strong accumulation of cyclin A was observed in the cytoplasm in cells expressing ESXR1 with a functional C-terminal region.
Given the potential DNA binding activity of the paired-like homeodomain, nuclear localization of ESXR1-N raises the idea that it functions as a transcription factor. To address this possibility, we generated a chimeric molecule consisting of GAL4-DNA binding domain and the full-length ESXR1 (GAL4-WT), the N-terminal ESXR1 (GAL4-DC), or the C-terminal ESXR1 (GAL4-DN). Each of the chimeric protein was coexpressed together with the reporter gene construct, in which the GAL4-binding sequence was inserted upstream of the SV40 promoterluciferase gene transcriptional unit, in U2-OS cells. As shown in Figure 11 , GAL4-WT or GAL4-DC was capable of inhibiting promoter activity, whereas GAL4-DN failed to do so. The observation indicates that ESXR1-N can act as a transcriptional repressor.
Discussion
In this work, we isolated a paired-like homeobox gene ESXR1 by screening human cDNA that can rescue yeast cells from lethality caused by ectopic expression of human cyclin E. ESXR1 was recently cloned based on its sequence homology with a mouse paired-like homeobox gene, Esx1/SPX1 (Fohn and Behringer, 2001 ). The paired-like homeodomain of the ESXR1 product ESXR1 exhibits 65% identity with that of mouse Esx1/SPX1. In adult mouse, Esx1/SPX1 expression has been detected in male pre-and postmeiotic germ cells, indicating that Esx1/SPX1 plays a role in spermatogenesis (Branford et al., 1997; Li et al., 1997) . Since human ESXR1 is also specifically expressed in adult testis, it is reasonable to speculate that the two gene products play similar or identical roles in spermatogenesis through the conserved homeodomains. Considering that many if not all of the paired-like homeoproteins mediate transcriptional processes in eukaryotic cells, mouse Esx1/SPX1 and human ESXR1 may act as sequence-specific transcription factors regulating a particular set of genes during spermatogenesis. Consistent with this idea, we have recently found that the ESXR1 homeodomain binds a specific DNA sequence (unpublished observation). Outside the homeodomain, however, ESXR1 has no significant sequence homology with Esx1/SPX1 or any other proteins.
We report in this work a novel activity of ESXR1: it induces accumulation of cyclins such as cyclin A, cyclin E and cyclin B1, by preventing their degradation independently of the cell cycle phase. We conclude that ESXR1 prevents degradation of poly-ubiquitinated cyclins by the 26S proteasome pathway. As a result, cyclin turnover is impaired, giving rise to elevated levels of non-ubiquitinated cyclins (Figure 5a, b) with prolonged biological half-life of nonubiquitinated cyclins (Figure 5d) .
In contrast to cyclins, ESXR1 is incapable of stabilizing p130 and b-catenin, both of which are also known to be regulated by the ubiquitin-26S proteasome system (Aberle et al., 1997; Tedesco et al., 2002) . The apparent specificity of ESXR1 toward cyclins suggests that the protein is involved in the regulation of a certain set of polyubiquitinated proteins including cyclins. Recent studies have demonstrated that cyclin A is required for G2/M transition and subsequent M-phase progression until metaphase (Furuno et al., 1999) . Hence, inhibition of cyclin A degradation appears to be primarily responsible for the cell cycle delay/arrest at early M phase by ESXR1. Indeed, cells arrested by ESXR1 exhibited immature chromosome condensation without a nuclear membrane breakdown. Since ESXR1 is also capable of inhibiting cyclin B1 degradation when enforcedly expressed in metaphase-arrested cells, it has an ability to inhibit degradation of multiple cyclin species. The finding then indicates that ESXR1 interacts with cell machineries that are commonly involved in cyclin degradation rather than those specific to each cyclin species. However, it is also clear that a primary target of ESXR1 in cycling cells is cyclin A because ectopic expression of ESXR1 in asynchronously proliferating cells gives rise to prophase arrest as a result of inhibition of cyclin A degradation.
In human tissues, ESXR1 is specifically expressed in the testis. The prophase of the male first meiotic division is a lengthy process that ensures the correct pairing and the crossing over between homologous chromosomes (Sette et al., 1999) . Accordingly, ESXR1 may act as a key regulator for mitosis, and probably meiosis as well, in male germ cells by delaying cell cycle progression from G2 to meiosis I. Mouse Esx1/SPX1 is downregulated in meiotic stages (Branford et al., 1997) . If this is also the case with ESXR1, then its downregulation might be required for human spermatogenic cells to enter into meiosis.
The 65-kDa full-length ESXR1 protein is capable of proteolytically processing into N-terminal 45-kDa and C-terminal 20-kDa fragments in the cells. The 45-kDa fragment, ESXR1-N, contains a homeodomain, whereas a 20-kDa fragment, ESXR1-C, possesses a proline-rich domain consisting of 15 contiguous repeats of a GPPMAP(V/L)PP motif that is not conserved in mouse Esx1/SPX1. Instead, mouse Esx1/SPX1 possesses another unique motif, termed the PF/PN motif, consisting of an alternating repeat of proline and phenylalanine residues by proline and asparagine residues, in the corresponding region. Yan et al. (2000) recently reported that the PF/PN motif inhibits nuclear localization of Esx1/SPX1, by masking the NLS located in other regions of Esx1/SPX1. Since the 65-kDa full-length ESXR1 protein is present in the cytoplasm, the Cterminal ESXR1 region might also have a regulatory mechanism similar to that of Esx1/SPX1. However, at the same time, the structural diversity of the C-terminal regions between ESXR1 and Esx1/SPX1 reinforces the notion that the two proteins have acquired biological activities unique to each other during evolution. It should also be noted that there is no report on proteolytic processing of mouse Esx1/SPX1.
The mechanisms of ubiquitin conjugate formation, disassembly, and conjugate degradation are conserved from yeast to mammalian cells. Accordingly, the observation that ESXR1 rescued yeast cells from cyclin E toxicity suggests that there exists a molecule structurally related to a human target of ESXR1 in yeast cells. The unique GPPMAP(V/L)PP motif might provide a binding site for the assumed ESXR1 target. One possible scenario is that such a molecule is present as a component of the ubiquitin-proteasome system in the cytoplasm and acts as a negative regulator of ubiquitinated cyclin degradation in yeast. Upon complex formation, ESXR1 might impair its inhibitory activity and thereby promote degradation of cyclin E, conferring yeast cells resistant to cyclin E overexpression. In contrast, in human cells, the assumed ESXR1 target may function as a positive regulator, rather than negative regulator, of the ubiquitin-proteasome system in the cytoplasm. In fact, it is well known that molecules that are highly conserved throughout species do not always execute same functions among different species. For example, yeast Ras is involved in G protein-coupled signaling, whereas human Ras plays an important role in mitogenic signal transduction. Furthermore, cyclin E overexpression in wild-type yeast is lethal (Mumberg et al., 1994) , while it rescues triple G1 cyclin (cln1, cln2, cln3)-deficient yeast cells (Lew et al., 1991) . Accordingly, the effect of ESXR1 in yeast may not necessarily be explained by the biological activity of ESXR1 in human cells. With this notion in mind, the mechanism by which ESXR1 rescues yeast cells from cyclin E toxicity warrants further investigation.
The 65-kDa full-length ESXR1 protein and ESXR1-C, both of which are present in the cytoplasm, may bind the target and inhibit its activity to promote cyclin degradation. In contrast, ESXR1-N is exclusively localized to the nucleus due to the presence of the NLS in homeodomain. The strict nuclear localization supports the idea that ESXR1-N is actively involved in gene regulation. Consistently, the N-terminal ESXR1 region possesses a transcriptional repressor activity.
Proteolytic processing of the 65-kDa full-length ESXR1 protein is capable of generating two biologically active fragments. The role of protein processing in transcriptional regulation has been well characterized as represented as the cases of NF-kB (Naumann et al., 1993) and STAT5 (Azam et al., 1997) . Among others, processing of ESXR1 is novel in that it generates two peptide fragments that respectively exhibit distinct biological activities in different intracellular compartments: one functions in the cytoplasm as a cell cycle regulator and the other may act as a transcriptional regulator in the nucleus. An intriguing idea is therefore that the full-length ESXR1 and the two ESXR1 fragments work in concert to coordinate the cell cycle and cell differentiation programs during spermatogenesis. Our work points to a critical role of proteolytic processing in coordinating distinct biological activities.
Materials and methods
cDNA cloning
A diploid S. cerevisiae strain that expresses human cyclin E cDNA under the GAL promoter was constructed as follows. After subcloning cyclin E cDNA in p413GALS, the PvuII fragment containing the GALS promoter, cyclin E cDNA, and the CYC terminator was excised and inserted at the HpaI site of the 2.2 kb XhoI-SalI fragment containing LEU2. Haploid strains TM142 (MATa ura3 leu2 trp1 his3) and TM244 (MATa ura3 leu2 his3 lys2) were transformed with this construct, and then the resultant strains with the cyclin E expression cassette integrated in their genome were obtained. These strains were mated to give rise to the diploid strain used for the following screening. The host strain was transformed with a HeLa cellderived human cDNA library constructed in pNV7 (Ninomiya-Tsuji et al., 1991) , and transformants that restored the growth on galactose-containing selective medium lacking uracil were selected.
Construction of plasmids
cDNAs encoding wild-type ESXR1, ESXR1DC (amino acids 1-229), ESXR1DHD (amino acids , Myc-ESXR1-Flag, C-terminal triple HA-tagged cyclin A, cyclin B1, and cyclin E were subcloned into pcDNA3. The ESXR1DN mutant (amino acid residues 230-406) and p130 tagged with Cterminal HA were subcloned into pcDNA3 or pSP65-SRa. pCIneo/Flag-ubiquitin was a gift from Dr H. Yokosawa (Hokkaido University, Sapporo, Japan).
Cell culture
U2-OS, HeLa, COS-7 and JKT-1 cells were cultured in DMEM containing 10% fetal bovine serum (FBS). NCC-IT and AGS cells were cultured in RPMI 1640 medium containing 10% FBS. To establish U2/tetESXR1, which inducibly expresses Myc-ESXR1, pOPTET-BSD/Myc-ESXR1 was transfected into U2-OS-derived Tet-on cells (CLONTECH) by calcium phosphate precipitation method.
Antibodies
Antibodies to Cdk2, cyclin A, cyclin E, HA, p130 and competing Cdk2 peptide were from Santa Cruz Biotechnology. Antibody for cyclin B1 was from PharMingen. Anti-Flag antibody was from Sigma. Antibody for b-catenin was from Transduction Laboratory. Antibody for Myc was monoclonal antibody (9E10). Anti-ESXR1 antiserum was generated by immunizing rabbits with a synthetic peptide (MESLR-GYTHSDIGYRSL) corresponding to the N-terminal ESXR1 residues 1-17.
Northern blot analysis and RT-PCR
ESXR1 cDNA was used as a probe for mRNA detection in MTN blots (Clontech). Total RNA was extracted using TRIzol s Reagent (Invitrogen), reverse-transcribed using an oligo (dT) primer, and amplified by polymerase chain reaction (PCR) using two primers, 5 0 -ACCGCGTTCACGCAGTTTCAG-3 0 and 5 0 -GGCATAGGTGCTATGGGTGG-3 0 .
Western blot analysis
U2-OS cells were transiently cotransfected with 20 mg of Myctagged ESXR1 expression vector and 2 mg of HA-tagged cyclin A, cyclin B1, cyclin E or p130 expression vector using the calcium phosphate precipitation method. After 40 h of culture, the transfected cells were harvested and the cell lysates were subjected to SDS-PAGE as described previously (Ashizawa et al., 2001) . Tissue-specific protein concentrates (testis 7808-1, placenta 7806-1, Clontech) were used for tissue blot.
Transfection of siRNA
Synthetic siRNAs were purchased from Greiner Bio-One. The ESXR1-specific siRNA molecules used in this study have the following sequences: 5 0 -CUCAGGUUUGGACCGUGUATT-3 0 and 5 0 -UACACGGUCCAAACCUGAGTT-3 0 . The nonsilencing siRNA from Greiner Bio-One, which does not target any known mammalian gene, was used as the negative control. U2/tetESXR1 cells were transfected with synthetic siRNA using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol. At 12 h post-transfection, 2 mg/ml Dox were added to the culture. The transfected cells were harvested at 60 h post-transfection. HeLa cells were transfected with synthetic siRNA as described. At 48 h, siRNA transfection was repeated once again and the transfected cells were harvested at 96 h postprimary transfection.
Immunofluorescence U2-OS cells were transiently transfected with 150 ng of wildtype or mutant ESXR1 expression vector using Lipofectamine 2000 reagent. At 40 h post-transfection, the cells were fixed with 10% formalin. Primary antibodies were localized by Alexa Fluor 546-conjugated anti-rabbit or Alexa Fluor 488-conjugated anti-mouse antibody (Molecular Probes). The nuclei were stained with 50 ml of PI-solution containing 100 mg/ml RNase A for 30 min. Images were acquired using a confocal microscope system (Fluoview, Olympus).
In vitro kinase assay
GST, GST-ESXR1 or GST-p21
Cip1 produced in E. coli and recombinant cyclin E-Cdk2 produced in baculovirus were incubated for 20 min at room temperature. The protein mixture was then added to kinase reaction (20 mM Tris-Cl pH 7.4, 10 mM MgCl 2 , 4.5 mM 2-mercaptoethanol, 1 mM EGTA, 50 mM ATP, 4 mCi [g-32 P]ATP and 1.4 mg of histone H1). The reaction mixture was incubated for 30 min at 301C and was subjected to SDS-PAGE. Phosphorylated proteins were visualized by autoradiography.
Pulse-chase experiments
U2/tetESXR1 cells were cultured in the presence of 5 mM HU for 24 h and were added 2 mg/ml Dox. After 24 h, HU was removed from the culture plates, and then cultured for 2 h. The cells were labeled with 100 mCi/ml Tran 35 S-methionine and cysteine (ICN) for 2 h. The cells were then chased for the indicated times. Cell lysates were immunoprecipitated with anti-cyclin A antibody. The cyclin A protein was quantified using a PhosphorImager (FLA-3000, FUJIFILM).
